Please login to the form below

Not currently logged in
Email:
Password:

drug treatment

This page shows the latest drug treatment news and features for those working in and with pharma, biotech and healthcare.

AZ/Merck's Lynparza improves survival in certain prostate cancers

AZ/Merck's Lynparza improves survival in certain prostate cancers

New data released at ESMO 2020 virtual congress shows drug cuts the risk of death. ... Lynparza was approved in May by the US Food and Drug Administration (FDA) for the treatment of previously-treated metastatic mCRPC patients with mutations in their HRR

Latest news

  • BMS eyes approval for second Opdivo combo in kidney cancer BMS eyes approval for second Opdivo combo in kidney cancer

    plus tyrosine kinase inhibitor (TKI) Cabometyx (cabozantinib) compared to Pfizer’s older drug Sutent (sunitinib). ... However, it has been facing competition from Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus

  • Shionogi's Gram-negative antibiotic launches in the UK Shionogi's Gram-negative antibiotic launches in the UK

    The launch of Shionogi's Fetcroja (cefiderocol) in the UK is its first after the drug gained European Commission approval earlier this year, and is the first treatment which protects against ... In the US, Shionogi’s drug is approved under the name

  • Novartis wins FDA approval for relapsing MS drug Kesimpta Novartis wins FDA approval for relapsing MS drug Kesimpta

    The US Food and Drug Administration (FDA) has approved Novartis’ relapsing multiple sclerosis (MS) treatment Kesimpta, one of the company’s most promising growth drivers as identified by CEO Vas Narasimhan. ... Roche’s drug is also the only drug

  • Speed kills Speed kills

    On 22 May, The Lancet published a research paper about hydroxychloroquine, the antimalarial drug, as a potential treatment for COVID-19. ... In a wide-ranging interview with The Lancet’s editor, Richard Horton, the New Yorker notes that “unlike other

  • FDA approves Sarepta rival NS Pharma’s Duchenne drug FDA approves Sarepta rival NS Pharma’s Duchenne drug

    NS Pharma’s drug has been approved for the treatment of DMD patients who have a confirmed mutation of the DMD gene with exon 53 mutations. ... It is the company’s second DMD drug after Exondys 51 (eteplirsen), the first disease-modifying treatment

More from news
Approximately 0 fully matching, plus 895 partially matching documents found.

Latest Intelligence

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    This influx of capital means there are already close to 200 start-ups using AI in drug discovery. ... Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.

  • AI and genomics: a revolution in drug discovery and development AI and genomics: a revolution in drug discovery and development

    Other purposes. The approach can be applied later in the drug development process. ... Gardner concluded: “Many pharmaceutical companies are looking at repurposing: does an approved drug have potential as a treatment for a new condition?

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    An experimental antiviral: Gilead’s remdesivir. Gilead’s remdesivir, an experimental antiviral drug, is arguably the most-talked about potential treatment for COVID-19. ... The combination drug was first included in Chinese health authorities’

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    But just as Big Tech has disrupted plenty of other industries, there is every reason to think that it will be interested in the opportunities to move more into drug therapy ... a cool $63bn (which was also notable for putting the world’s best-selling

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Daiichi's partner AZ paid a massive  $1.35bn upfront for rights to the drug, and after being given a priority review by the FDA as a treatment for patients with ... In the DESTINY-Breast01 trial, the drug showed a 60% response rate in patients who had

More from intelligence
Approximately 0 fully matching, plus 46 partially matching documents found.

Latest appointments

  • Finland's Faron Pharmaceuticals appoints new medical director Finland's Faron Pharmaceuticals appoints new medical director

    In his new role he will join Turku-based Faron's executive management team and oversee its drug development strategy, including its clinical programmes for Traumakine and Clevegen. ... Our lead drug candidate Traumakine, for the treatment of Acute

  • Canbex hires former Lilly medical director Canbex hires former Lilly medical director

    As chief medical officer at Canbex Dr Lledó will lead preparations for proof of concept trials for the company's lead candidate VSN16R, an oral drug intended for the treatment of ... As a practicing neurologist and experienced drug developer, I am very

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...

Infographics